Revolution Medicines Reports 42% Response Rate for Elironrasib in Pretreated KRAS G12C NSCLC

Elironrasib, a novel RAS(ON) G12C-selective inhibitor developed by Revolution Medicines, has shown promising clinical efficacy in heavily pretreated patients with metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC), including those who had progressed after prior treatment with first-generation KRAS(OFF) G12C inhibitors. In a Phase 1 trial, 42% of patients experienced partial responses, with a disease control rate of 79%, a median duration of response of 11.2 months, and a median progression-free survival of 6.2 months. These results suggest that targeting the active, GTP-bound form of KRAS G12C may overcome resistance mechanisms limiting the durability of current therapies like sotorasib and adagrasib. The drug was well tolerated at the recommended Phase 2 dose of 200 mg orally twice daily. Revolution Medicines highlighted these findings at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, underscoring elironrasib's potential to create new global standards of care for patients with KRAS G12C NSCLC. The company continues to advance its RAS(ON) inhibitor platform, aiming to develop effective therapies against RAS-driven cancers.